COST-EFFECTIVENESS OF RITUXIMAB-BASED CHEMOTHERAPY COMBINATIONS FOR THE INTIAL THERAPY OF FOLLICULAR LYMPHOMA

被引：0
|
作者：
Shah, G. [1 ]
Winn, A. [2 ]
Kumar, A. [3 ]
Lin, P. [3 ]
Parsons, S. [3 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Univ North Carolina Chapel Hill, Chapel Hill, NC USA
[3] Tufts Med Ctr, Boston, MA USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY70
引用
收藏
页码：A221 / A221
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of rituximab in follicular lymphoma
    Johnston, Karissa M.
    Bolbocean, Corneliu
    Connors, Joseph
    Peacock, Stuart
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2012, 12 (05) : 569 - 577
  • [2] Cost-effectiveness of rituximab maintenance therapy for patients with follicular lymphoma: The Spanish perspective
    Gomez Codina, J.
    Provencio, M.
    Rueda, A.
    Capote, F.
    Carbonell, F.
    Conde, E.
    Fernandez Ranada, J.
    Giraldo, P.
    Rios, E.
    Varela, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Comparison of Survival and Costs of Rituximab-Based Chemotherapy for Initial Therapy of Follicular Lymphoma in Elderly Patients
    Shah, Gunjan L.
    Winn, Aaron
    Lin, Pei-Jung
    Kumar, Anita J.
    Parsons, Susan K.
    BLOOD, 2016, 128 (22)
  • [4] THE COST EFFECTIVENESS OF RITUXIMAB MAINTENANCE THERAPY IN PATIENTS WITH FOLLICULAR LYMPHOMA
    Mervin, M. C.
    VALUE IN HEALTH, 2016, 19 (03) : A153 - A153
  • [5] EVALUATING THE COST-EFFECTIVENESS OF THE ADDITION OF RITUXIMAB TO CHEMOTHERAPY IN THE FIRST LINE TREATMENT OF FOLLICULAR LYMPHOMA PATIENTS IN THE UK
    Rafia, R.
    Papaioannou, D.
    Stevenson, M.
    Rathbone, J.
    Woods, H. B.
    VALUE IN HEALTH, 2011, 14 (07) : A445 - A445
  • [6] Cost-Effectiveness of Obinutuzumab Plus Chemotherapy Versus Rituximab Biosimilars Plus Chemotherapy for Patients with Previously Untreated Follicular Lymphoma
    Veenstra, David L.
    Guzauskas, Gregory F.
    Spencer, Scott J.
    Felizzi, Federico
    Launonen, Aino
    Dawson, Keith
    Masaquel, Anthony
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S280 - S280
  • [7] Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy
    Hornberger, John
    Chien, Rebecca
    Friedmann, Mark
    Han, Leona
    Shewade, Ashwini
    Satram-Hoang, Sacha
    Reyes, Carolina
    LEUKEMIA & LYMPHOMA, 2012, 53 (12) : 2371 - 2377
  • [8] Cost-Effectiveness Analysis of Maintenance Therapy with Rituximab in Patients with Follicular Lymphoma Responding to Induction Therapy at the First Line
    Castro Gomez, Antonio J.
    Lopez-Guillermo, Armando
    Rueda Dominguez, Antonio
    Salar, Antonio
    Varela Moreno, Cristina
    Rubio-Terres, Carlos
    REVISTA ESPANOLA DE SALUD PUBLICA, 2012, 86 (02): : 163 - 176
  • [9] Cost-Effectiveness of Rituximab As Maintenance Treatment for Relapsed Follicular Lymphoma: Results of a Population Based Study
    Blommestein, Hedwig M.
    Issa, Djamila E.
    Pompen, Marjolein
    Revil, Cedric
    Hoogendoorn, Mels
    Joosten, Peter
    Zweegman, Sonja
    Huijgens, Peter C.
    Uyl-de Groot, Carin A.
    BLOOD, 2012, 120 (21)
  • [10] Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden
    Kasteng, Frida
    Erlanson, Martin
    Hagberg, Hans
    Kimby, Eva
    Relander, Thomas
    Lundkvist, Jonas
    ACTA ONCOLOGICA, 2008, 47 (06) : 1029 - 1036
12345